Bayer Paid $63 Billion for a Lawsuit It Could Read in Advance

In March 2015, a World Health Organization agency put a label on glyphosate — the active ingredient in Roundup — that no buyer of a chemical company wants to read: probable human carcinogen.⁷ That was more than a year before Bayer made its first offer for Monsanto. By the time Bayer wired the money and closed the deal on June 7, 2018, Monsanto was already in court defending over 120 toxic-tort cases.⁷ None of this was hidden. It was on the public record, sitting in plain sight, waiting in the data room. Bayer read it, weighed it, and paid $128 a share anyway — roughly $63 billion once you fold in Monsanto's debt.¹

The official story is that Bayer made a bold bet on agriculture and got blindsided by an unforeseeable wave of litigation. The honest version is harsher: the wave was forecast, posted, and dated before the deal closed. This wasn't a company surprised by a hidden defect. It was a company that bought a lawsuit it could read in advance — and then told investors the diligence had been 'exhaustive.'⁷

The risk wasn't buried. It was published.

Counterfactual analysis lives or dies on one question: what did the decision-maker know, and when? In most M&A disasters the buyer can plausibly claim ambush — a fraud surfaced later, a market turned, a technology obsolesced. Bayer cannot. The two facts that would eventually cost it tens of billions were both timestamped before its May 2016 offer. The carcinogen classification was a year old.⁷ The litigation docket already ran past 120 cases.⁷ A buyer staring at those two numbers is no longer making a bet on an unknown. It is choosing to absorb a known, growing liability — and pricing it at zero.

That gap — between what was knowable and what was claimed — is the whole case. The securities class action settled for $38 million, a number approved by a federal judge in 2025.⁷ By itself, $38 million is a rounding error against a $63 billion deal. But it is the cheapest, clearest piece of evidence that the litigation risk was not a black swan. It was a known input that the diligence process was supposed to price, and didn't.

The arithmetic of walking away

Here is the counterfactual stated plainly. The road Bayer took: pay $128 a share, take on $20 billion in new bonds to finance it², watch roughly 40% of market capitalization evaporate after closing⁸, announce a $10.1–$10.9 billion settlement in 2020³, and keep paying — over $11 billion out the door, with billions more in reserves against ongoing claims.³ The road not taken: pay the break-up cost of an abandoned deal and keep the company you already had. When the litigation bill alone dwarfs the premium you paid, the counterfactual stops being a thought experiment and becomes simple subtraction. Even accounting for the $2 billion reverse break-up fee written into the merger agreement, it was structurally cheaper not to own the asset at all.

The damage was not abstract. At Bayer's 2019 annual meeting, 55.5% of shareholders voted no confidence in CEO Werner Baumann over the deal — the lowest approval rate in Germany's postwar corporate history, according to the Financial Times — a historic rebuke for a sitting chief executive of a blue-chip German firm.¹¹ The owners of the company had done the same arithmetic and reached the same verdict the counterfactual produces: this should not have closed.

The fair objection: it wasn't all Roundup, and the law later turned

The honest counter has two parts, and both have teeth. First, the market-cap destruction was multi-causal. Analysts pointed to a thinning pharmaceutical pipeline and looming patent cliffs on Xarelto and Eylea starting in 2023, and to the acquisition debt that left Bayer unable to chase the pharma deals it needed.⁸ Roundup was the proximate trigger, not the sole cause. Second — and this is the part that complicates the indictment — the law eventually moved Bayer's way. In June 2026 the Supreme Court ruled 7-2 in Monsanto v. Durnell that federal pesticide law preempts state failure-to-warn claims where the EPA never required a cancer label, blocking thousands of suits.¹² If you'd known that ruling was coming in 2018, the deal looks a lot less reckless.

But notice what each objection concedes. The pipeline weakness doesn't exonerate the deal — it indicts it harder, because the acquisition debt constrained Bayer's ability to pursue the pharma investment the pipeline required.⁸ And the 2026 court win arrived eight years and over $11 billion too late.⁶ A favorable ruling that lands after you've paid out a fortune and lost your CEO doesn't rescue the decision; it only proves the cost of holding the position long enough to be vindicated. A good outcome you had to bleed for eight years to reach is not a good bet. It is an expensive escape from a hole you didn't have to dig.

Strip the strategy deck away and the Monsanto deal reduces to a single, stubborn fact: every input needed to predict the disaster was published, dated, and available before Bayer signed. The carcinogen label existed. The lawsuits existed. The break-up option existed. The company chose the one path that turned all three into a $16 billion bill and a 40% haircut — then called the diligence thorough.⁷ The counterfactual isn't a clever exercise here. It's the cheaper company that was sitting right next to the expensive one, separated by a single decision Bayer had every fact in hand to get right.